A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

None had been diagnosed with Alzheimer disease and related dementias at the start of the study. The researchers discovered that people who took GLP-1 receptor agonists (like Ozempic) or a type of ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two common anti-diabetes ...

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been hailed ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.